{"organizations": [], "uuid": "64e36c3ab8a79cb6a2cb0610908f8f6cb439c463", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/10/globe-newswire-viveve-reports-first-quarter-2018-financial-results.html", "country": "US", "domain_rank": 767, "title": "Viveve Reports First Quarter 2018 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.997, "site_type": "news", "published": "2018-05-11T00:07:00.000+03:00", "replies_count": 0, "uuid": "64e36c3ab8a79cb6a2cb0610908f8f6cb439c463"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/10/globe-newswire-viveve-reports-first-quarter-2018-financial-results.html", "ord_in_thread": 0, "title": "Viveve Reports First Quarter 2018 Financial Results", "locations": [], "entities": {"persons": [{"name": "scott durbin", "sentiment": "none"}, {"name": "viveve", "sentiment": "none"}], "locations": [{"name": "englewood", "sentiment": "none"}, {"name": "colo.", "sentiment": "none"}], "organizations": [{"name": "viveve medical inc.", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Continued quarter-over-quarter annual revenue growth and rapid expansion into stress urinary incontinence market planned for Viveve® System\nENGLEWOOD, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- Viveve Medical Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported its financial results for the quarter ended March 31, 2018.\n“For the first quarter of 2018, Viveve recorded sales of $3.7 million demonstrating strong global demand and increasing enthusiasm from physicians for our innovative cryogen-cooled monopolar radiofrequency technology and its clinical applications. We also reached a number of significant milestones that support our global commercialization strategy and set the stage for continuing global adoption of the Viveve® System through the remainder of 2018,” said Scott Durbin, chief executive officer and director of Viveve.\nQ1 2018 Business Highlights\nReceived U.S. Food and Drug Administration (FDA) approval of an Investigational Exemption Device (IDE) to conduct VIVEVE II, a multicenter randomized double blinded sham-controlled trial using the Viveve System for the improvement of sexual function; Announced expansion of its cryogen-cooled monopolar radiofrequency (CMRF) technology platform into the Stress Urinary Incontinence (SUI) market; Reported positive 12-month results from the SUI pilot study conducted by Dr. Bruce Allan in Calgary, Alberta; Announced plans to conduct clinical registration studies to further assess the safety and efficacy of the Viveve System in the treatment SUI; Received regulatory approvals in three Latin America countries; Secured financing of approximately $32.4 million in a February common stock offering.\nQ1 2018 Financial Results\nRevenue for the first quarter of 2018 totaled $3,699,000 from the sale of 53 Viveve systems, 38 of which were sold in North America through direct sales, and approximately 5,400 disposable treatment tips making the company’s current global installed base as of March 31, 2018 – 497 systems, compared to revenue of $3,041,000 for the same period in 2017, a 22% year-over-year quarterly revenue growth.\nGross profit for the first quarter of 2018 was $1,347,000, or 36% of revenue, compared to gross profit of $1,422,000 or 47% of revenue, for the same period in 2017. The decrease was primarily due to the change in the mix of products sold in the first quarter of 2018.\nTotal operating expenses for the first quarter of 2018 were $12,687,000, up from $7,838,000 in the same period in 2017, mainly a result of increased costs to support commercialization in North America markets, product development efforts, regulatory and clinical study activities, strategies to protect Viveve’s intellectual property and other general corporate expenses.\nNet loss for the first quarter of 2018 was $12,669,000, or ($0.49) per share, compared to a net loss of $6,695,000, or ($0.57) per share, for the same period in 2017.\nCash and cash equivalents were $38,378,000 as of March 31, 2018, which includes the recent equity financing that concluded in February 2018.\n2018 Financial Guidance\nViveve continues to anticipate rapid commercial growth and reiterates its 2018 guidance for annual revenue of $22 million to $24 million.\nConference Call Information\nThe company will host a live conference call at 5:00 pm ET today. The conference call may be accessed by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international) or via live webcast at http://services.choruscall.com/links/vive180510.html . Participants may also pre-register for the conference call at http://dpregister.com/10119472 .\nA recording of the webcast will be posted on the company’s investor relations website following the call at http://ir.viveve.com and will be available online for 90 days.\nAbout Viveve\nViveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the Viveve treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in a single 30-minute in-office session.\nInternational regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications from over 55 countries. Viveve received approval of an Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA) in March of 2018 to proceed with VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth. Initiation of the trial is expected to begin in the second quarter of 2018 and if successful, could support a marketing application for a new U.S. commercial indication. Currently, , the Viveve System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis.\nViveve has submitted an Investigational Trial Application to the Canadian Ministry of Health and plans to submit an IDE to the FDA to conduct two independent multicenter randomized registration trials (LIBERATE-International and LIBERATE-U.S. respectively) for use of the CMRF device in stress urinary incontinence treatment.\nInControl Products by Viveve are FDA cleared medical devices that treat stress, urge, and mixed incontinence conditions and products to improve pelvic floor strength. Viveve exclusively distributes InControl Medical's products to healthcare providers .\nFor more information visit Viveve's website at www.viveve.com .\nSafe Harbor Statement\nAll statements that are not based on historical fact are \" \" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any included on its current expectations, the information on which such expectations were based may change. These rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov . Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise to reflect events or circumstances that subsequently occur or of which we hereafter become aware.\nViveve is a registered trademark of Viveve, Inc.\nInvestor Relations contacts:\nSarah McCabe\nStern Investor Relations, Inc.\n(212) 362-1200\nsarah@sternir.com\nAmato and Partners, LLC\nInvestor Relations Counsel\nadmin@amatoandpartners.com\nMedia contact:\nKelly Wakelee\nBerry & Company Public Relations\n(212) 253-8881\nkwakelee@berrypr.com\nVIVEVE MEDICAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) March 31, December 31, 2018 2017 ASSETS Current assets: Cash and cash equivalents $ 38,378 $ 20,730 Accounts receivable, net 6,999 6,213 Inventory 3,828 2,390 Prepaid expenses and other current assets 3,302 2,741 Total current assets 52,507 32,074 Property and equipment, net 1,674 1,303 Investment in limited liability company 2,251 2,500 Other assets 204 202 Total assets $ 56,636 $ 36,079 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 3,865 $ 4,799 Accrued liabilities 4,257 4,605 Total current liabilities 8,122 9,404 Note payable, noncurrent portion 29,334 28,948 Other noncurrent liabilities 218 327 Total liabilities 37,674 38,679 Stockholders’ equity (deficit): Common stock and additional paid-in capital 137,035 102,981 Accumulated deficit (118,073) (105,581) Total stockholders’ equity (deficit) 18,962 (2,600) Total liabilities and stockholders’ equity (deficit) $ 56,636 $ 36,079\nVIVEVE MEDICAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (unaudited) Three Months Ended March 31, 2018 2017 Revenue $ 3,699 $ 3,041 Cost of revenue 2,352 1,619 Gross profit 1,347 1,422 Operating expenses: Research and development 3,756 2,388 Selling, general and administrative 8,931 5,450 Total operating expenses 12,687 7,838 Loss from operations (11,340) (6,416) Interest expense, net (1,070) (263) Other expense, net (10) (16) Net loss from consolidated companies (12,420) (6,695) Loss from minority interest (249) - Net loss $ (12,669) $ (6,695) Net loss per share: Basic and diluted $ (0.49) $ (0.57) Weighted average shares used in computing net loss per common share: Basic and diluted 25,846,724 11,663,765\nSource:Viveve Medical, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=QSsfewxQ7OwH_Ew9X7ztb-NWOVIt1QiBWrO2uWkCnm58Wlq5T78BiDCnsEIZxdg_Y5IESM7aBqBbNHrJGwlWp-XGE_4ibzVmdy5FQaIyjQ4O_qiwABLwTMrBTMtGYtpe7clIKkOJS9ROmhFCt5MFvQanHkoot7LrQf-rmFT-Ck5X_mzvY9MJH7ivKBDc5jSBXNzGXu-V4uPPwhIbJoEQn4IwQonR9G1FZT1ulTMOy5s55sbVUbBkCPNWyNWRchschU4B2oE-jv-I1BE7VtzrG9g7U96l8iOEJxLsMBAp0Dk=", "https://www.globenewswire.com/Tracker?data=rz1jwxudNVyPc94y06dcZ7VfP-6Gk8cZ7RCKj2FsZFKagPBphIh2rnXTpdNgd9P-pRJwwIgUJCl6pACH90SzU5vTN8ppxi-tCcCepS6PUzptdfadBhNYU2PrvFGIDBWb", "http://dpregister.com/10119472", "https://www.globenewswire.com/Tracker?data=x7jpg_t6pVuquQ9JAz_kMTWURmJuzDeuTVoml4L79ksOKACBPme5d6uObOtuwRchGOZJGYs3XMZpaYMOobpTSMYkqlzR8TrKwTcevwxwtsk=", "http://services.choruscall.com/links/vive180510.html", "https://www.globenewswire.com/NewsRoom/AttachmentNg/172f78ab-bd68-4b01-902f-8dcfdec5bd35", "https://www.globenewswire.com/Tracker?data=QSsfewxQ7OwH_Ew9X7ztbxF_w2m9EIVS4o2N9I8xEWpxqqKj4cQ3hwwguSDvhYMcs1-_bZZDIS4jJtQqdqFCmOB5qYt088kQPn7QodeVeCLo0yuuuzZ241j2-WlGMG7Lgw5ucVX1AyV3k9j9gway_VLtn9Mt4VfNOLuDgU58pct1SElYXmV6yXnvSdVbo2BWnvivdmx0dtupsJiflrE2jNbUXUu-vNnsOvZIjEdiTXQ=", "https://www.globenewswire.com/Tracker?data=7OOb_2z4-ECWXCcBy03WGFxDQun64nJG7VYvl1laaB8owCUpIF8giOfCIm3-DC4Vm3THCob_F4DpjzNTh0TkwQ==", "https://www.globenewswire.com/Tracker?data=cIy1VmTxNxCE47mJxPuejvaWWKHbR6braUnzb9QdBeYxFF4SEUfXiyDzeaWi6g3Ap-yk1V5XSc_QgiuChCyMVROssXUuydzDiA6s0m46CvnLFvuM7QuelUYOOAyrKsXzN0NkKxtFNK1gXi7AUUWzL1bKfkd2YGW2cK3eiJcpqVSsB-QSbwdcCCZ0JK5NXuN2I_ia_fklcCjpz7aP00y2KQSrPTIU2zDxEUSJ9Z61MSk=", "https://www.globenewswire.com/Tracker?data=QSsfewxQ7OwH_Ew9X7ztb56fjqO2EFFiLIL_oJuDg97Vtx3wPYSzH9h6MlspTiPpK6bDM49Hft3jG38mabFpavmQDMJvhrxqAH5mXdcCf_PXSH41A3NF9MLh66dJNIQVco1WEzRjCqAkk6bQ-5t2Lk7jIUXWCERF1DC8VPmYUBZHTYIXui4NLOOYcsm4zD4KQ6LmKNz60_9W44Kdmuq0UbeNnTAxf-HAJgsM72exdpLyEdWQmjsPalMNBn7xgWA101kkpvQylS1FOkkKSNT12HlzgQbq2IK9KA_00zrEhU5KalMQES57JH5leVr6saNHOdHvHgXvsvCdpYhiXzBm2SsTaebnOqdZaVEI23aoMVlXz9if65acS_-Xk9OnbZgmOqk7v4BAgpFpF9hclEG39Q=="], "published": "2018-05-11T00:07:00.000+03:00", "crawled": "2018-05-11T01:12:15.004+03:00", "highlightTitle": ""}